Insiders who reported open-market trades in the last 12 months at the companies Mario Alberto Accardi files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Karen M. Anderson - $9.65M in CNTA purchases and sales in the last 12 months
Gregory M. Weinhoff - $2.65M in CNTA purchases and sales in the last 12 months
Tia L. Bush - $2.16M in CNTA purchases and sales in the last 12 months
Iqbal J. Hussain - $1.17M in CNTA purchases and sales in the last 12 months
Mario Alberto Accardi is a corporate insider, tracked as Chief Executive Officer, Director of Centessa Pharmaceuticals plc (CNTA). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Mario Alberto Accardi last file a Form 4?
The most recent primary Form 4 on record is dated 24 June 2026, one of 9 filings going back to 2025.
Has Mario Alberto Accardi been buying or selling stock?
Recorded transactions: 0 open-market purchases and 5 open-market sales ($642K) across all tracked filings.
Mario Alberto Accardi is Chief Executive Officer, Director of Centessa Pharmaceuticals plc (CNTA). 9 SEC Form 4 filings on record going back to 2025, most recently on 24 June 2026. Most recent open-market trade: sold $200K of CNTA on 27 October 2025. Lifetime open-market sales: $642K.
Recent transactions
13
The latest 13 SEC Form 4 transactions reported by Mario Alberto Accardi.
InsiderAlpha's records for Mario Alberto Accardi go back to 2025: 9 primary Form 4 filings, an average of 4.5 per year. 3 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
